CompletedPHASE1, PHASE2NCT04848974
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
Studying Therapy related acute myeloid leukemia and myelodysplastic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Tapan M KadiaM.D. Anderson Cancer Center
- Intervention
- Cladribine(drug)
- Enrollment
- 37 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04848974 on ClinicalTrials.gov